Concepedia

Brian Eastman

BE

Statistics

Publications

6

Citations

434

H-Index

6

Active since

2002

Affiliations

Pfizer (United States)(Current)

General Atomics (United States)

Newcastle University

Brian Eastman is an author at Pfizer (United States) specializing in pharmacology, medicinal chemistry, and medicine.

Publications per year

2002–2019

6

Publications

6

Tricyclic Benzimidazoles as Potent Poly(ADP-ribose) Polymerase-1 Inhibitors

Donald J. Skalitzky, Joseph Marakovits, Karen A. Maegley et al. · Journal of Medicinal Chemistry · 2002 · 152 citations · Full text

, , +16

The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models

Betty Y. Tam, Kevin Chiu, Heekyung Chung et al. · Cancer Letters · 2019 · 143 citations · Full text

, , +17

Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors

Alex W. White, Nicola J. Curtin, Brian Eastman et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 68 citations · Full text

, , +6

Structure-Based Design of a Parallel Synthetic Array Directed Toward the Discovery of Irreversible Inhibitors of Human Rhinovirus 3C Protease

Theodore Johnson, Hua Ye, Edward L. Brown et al. · Journal of Medicinal Chemistry · 2002 · 37 citations · Full text

, , +17

3-[3-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]-4-methylpyridine: a highly potent and orally bioavailable metabotropic glutamate subtype 5 (mGlu5) receptor antagonist

Steve F. Poon, Brian Eastman, Deborah F. Chapman et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 21 citations · Full text

, , +12

1–5 of 6